We are Sorry, This Page doesn't Exist
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Year-end reviews by the Food and Drug Administration produced mostly positive outcomes, with most therapies passing the regulatory hurdle without any hiccups. read more.....»»
Asia Markets: Asian markets mixed amid conflicting reports of tariff rollbacks
Asian markets were mixed in early trading Friday as investors sought clarity after conflicting messages about the state of U.S.-China trade talks......»»
Market Snapshot: Stocks trade mixed as Goldman, Citi kick off fresh batch of corporate earnings
U.S. stocks tread water Monday, as investors parse earnings from Goldman Sachs Group Inc., and Citigroup Inc., which could provide further guidance about the state of the banking sector and the broader economy......»»
CRE, Meeting high demand in Silicon Valley
Commercial real estate (CRE) continues to be a hot topic in Silicon Valley with investors, developers, and major employers staking claim to premier sites for business development. From Class A office space to innovative tech campuses and mixed-used dev.....»»
Student debt jumps at NC State, UNC, other NC schools
North Carolina’s average student debt is on the rise, according to LendEDU’s annual Student Loan Debt report. For the class of 2017, the average debt per borrower in North Carolina was $26,164, up 3.52 percent from the year prior, according to Len.....»»
Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech
Allakos Inc (NASDAQ: ALLK), a clinical-stage biotech company developing treatment for various eosinophil and mast-cell related diseases, offered 7.13 million shares in a.....»»
‘It didn’t seem like it was his forte’: Goldman Sachs CFO Marty Chavez is shifting roles after an unconvincing 18-month tenure (GS)
Twitter.com/GoldmanSachs Marty Chavez's reassignment as CFO of Goldman Sachs ends an 18-month tenure that was met with mixed reviews from analysts and investors. Chavez will return to a new ro.....»»
Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
After a strong 2017, biotech stocks are on track to end the year in the red despite a record 59 new molecular entity approvals, some noteworthy read more.....»»
On The Contrary: Focused Growth Strategy
For every hour the market was open in 2017 there was a net inflow of $29,539,973 into the three largest S&P 500 index ETF’s available to investors. Collectively, iShares, Vanguard and State Street.....»»
Does Boeing"s Q1 Earnings Beat Offer A Buy-The-Dip Opportunity While Investors Stay Bearish?
Boeing Co (NYSE:BA) is currently a mixed bag. The Arlington Co.....»»
UBS Upgrades China Stocks Amid "Valuation Collapse": What Investors Need to Know
UBS Group AG has upgraded China's stock market to Overweight, citing resilient earnings and state fund interventions. Other Asian markets downgraded. read more.....»»
City reviews Four Seasons hotel construction permit
Shad Khan's mixed-use development at the Shipyards is closer to construction on one of its largest pieces — the Four Seasons......»»
RTP firm sells more assets after struggling to raise money
The cash-strapped biotech is selling more assets after last year telling state officials it may have to lay off its entire staff......»»
2 more Chapter 11 bankruptcy filings from Nate Paul"s World Class hit courthouse
The World Class entities are tied to prime real estate properties in East Austin and the Rainey Street district. Many of the properties CEO Nate Paul has attempted to shield in bankruptcy court have ended up in the hands of other real estate investors......»»
Jim Cramer Weighs In On Fed"s Interest Rate Cut Plans: "Don"t Hold Your Breath. This Economy Doesn"t Need Them"
Cramer referred to the current state of the country as an "economic miracle," encouraging investors to consider the potential landscape if the Federal Reserve were focused on job creation rather than maintaining high rates to curb growth. read more.....»»
JPMorgan says the recent cryptocurrency plunge and shift into riskier altcoin bets looks a lot like the 2017 collapse
Josh Younger noted that like the end of the previous crypto bull cycle, investors are beginning to diversify out of bitcoin and ether and into riskier altcoins. Bitcoin replica coins are se.....»»
Kevin O"Leary says bitcoin is here to stay as an asset class, but the next wave of institutional money won"t come unless miners pivot towards renewable energy
Institutional investors are interested in bitcoin, so miners must ensure that it can meet firms' ESG standards, O'Leary told CoinDesk. Frederick M. Brown/Getty Images Kevin O'Leary reiterated his view .....»»
Crypto has become a full-fledged asset class, but prices are still dictated by FOMO and investors face barriers to entry, Goldman Sachs says
"If your closest rivals are all seeing material returns, your investors will wonder why you are not investing," says Goldman Sachs about the cryptocurrency market. .....»»
Column: California"s stem cell program found a disease cure, but it"s being blocked by a biotech firm
A biotech firm has halted work on a state-funded disease cure, purely for its bottom line.A biotech firm has halted work on a state-funded disease cure, purely for its bottom line......»»